Register for OBR daily

Kantar Health Conference Sidebar

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

RNN $0.73 0.0680 +10.27%
IMNP $3.79 0.2900 +8.29%
MRTX $18.07 1.3200 +7.88%
CBMG $18.40 1.2850 +7.51%
MGNX $20.15 1.3000 +6.90%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

TGTX $8.26 -1.3350 -13.92%
VRML $2.37 -0.1300 -5.20%
GERN $2.59 -0.1300 -4.78%
CNDO $1.64 -0.0600 -3.53%
CTIC $2.66 -0.0800 -2.92%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Next > | Last >>

Mayo Clinic Researchers Reveal Treasure Trove of Genes Key to Kidney Cancer

(Mayo Clinic) July 1, 2014 - A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer, say researchers from Mayo Clinic in Florida. Eight of these genes had not been previously linked to kidney cancer, and six other genes were never known to be involved in any form of cancer.
read press release 

JPMorgan's Dimon Has Throat Cancer, to Begin Treatment Shortly

(Reuters) July 2, 2014 - JPMorgan Chase & Co Chief Executive Officer Jamie Dimon said he has been diagnosed with throat cancer but that the ailment is curable and he plans to remain actively involved in the largest U.S. bank's business.
read article 

Everolimus Fails to Improve Overall Survival in Advanced HCC

(Medscape Medical News) July 1, 2014 - Everolimus (Afinitor) does not improve overall survival in patients with advanced hepatocellular carcinoma (HCC) whose disease had progressed on treatment with sorafenib (Nexavar), researchers report.
read article (free registration required) 

Roche to Pay Up to $1.7 Billion for Seragon Pharmaceuticals

(New York Times/DealBook) July 2, 2014 - The Swiss drug maker Roche Group said on Wednesday that it would pay up to $1.7 billion to acquire Seragon Pharmaceuticals, a privately held biotechnology firm focused on developing treatments for breast cancer.
read article 

Roche to Buy Cancer-Drug Maker for Up to $1.7 Billion

(Bloomberg) July 2, 2014 - Roche Holding AG agreed to buy Seragon Pharmaceuticals Inc. for as much as $1.7 billion to gain a new generation of experimental breast cancer treatments.
read article 

Liver Cancer Drug Fails to Live Up to Early Promise

(Philadelphia Inquirer/HealthDay News) July 1, 2014 - Although it looked promising in early studies, the drug everolimus didn't improve survival for people with advanced liver cancer in its latest trial, a new study found.
read article 

Study Finds Vaccine Side Effects Extremely Rare

(USA Today) July 1, 2014 - Serious complications related to vaccines are very rare, and there is no evidence that immunizations cause autism, according to an analysis of 67 research studies.
read article 

Sanofi Adds to Regeneron Stake

(Wall Street Journal) July 1, 2014 - Sanofi boosted its stake in Regeneron, though the French drug maker has said it doesn't plan to buy the research and development drug company.
read article (paid subscription required) 

U.S. Allows Actavis Plc's Purchase of Forest Labs With Conditions

(Reuters) June 30, 2014 - Generic drugmaker Actavis Plc has won U.S. approval to buy specialty pharmaceuticals company Forest Laboratories on condition it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.
read article 

Delay Hardship Deadline for EHR Meaningful Use, Doctors Say

(Medscape Medical News) June 30, 2014 - The federal government recently has given physicians several big breaks in keeping up with tougher requirements in its incentive program for using electronic health records (EHRs) in a meaningful way.
read article (free registration required) 

CWRU, UH Announce Collaborative Fundraising Initiative for Adolescent and Young Adult Cancer

(CWRU/The Daily) June 30, 2014 - Leaders from Case Western Reserve University and University Hospitals Monday announced a new collaborative fundraising effort focused on Adolescent and Young Adult (AYA) cancer.
read article 

Proton Therapy For Prostate Cancer: Time For Evidence

(The Lancet Oncology) July 2014 - On June 4, 2014, the American Society for Radiation Oncology (ASTRO) released its model policy on the use of proton beam therapy. The model policy is not intended to be a clinical guideline, but is the Society's recommendation for coverage policies.
read article 

Bruce Gould, MD Is New President of COA

(COA) July 1, 2014 - The Community Oncology Alliance (COA) announced that Bruce Gould, MD, Northwest Georgia Oncology Centers, Marietta, Georgia, has now assumed the position of president of COA.
read article 

NCCN to Host Policy Summit Addressing the Impact of Health Care Reform on Academic Oncology Practice

(NCCN) June 30, 2014 - On July 10, 2014, NCCN will host the NCCN Policy Summit: The Impact of Health Care Reform on Academic Oncology Practice, at The Westin Arlington Gateway in Arlington, Virginia, as part of the NCCN Oncology Policy Program.
read press release 

Ipsen Submits Marketing Authorization Applications in the US and Europe for Somatuline® (lanreotide) in the Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

(StreetInsider) July 1, 2014 - Ipsen Biopharmaceuticals, Inc., the U.S. affiliate of Ipsen today announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for Somatuline® Depot 120mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
read article 

Cancer Research UK Launches Visionary New Lung Cancer Centre of Excellence

(Cancer Research UK) July 1, 2014 - Cancer Research UK is bringing together leading researchers from London and Manchester in the groundbreaking new Lung Cancer Centre of Excellence at Manchester and UCL.
read press release 

Health ‘Passport’ Provides Guide For Pediatric Cancer Survivors

(PBS Newshour) June 30, 2014 - One of the biggest success stories in the fight against cancer has been the number of children who are surviving the disease. But ironically, the same treatments that are helping save so many lives can also cause a host of other health problems years later, and children who survive pediatric cancer are at particular risk. A wallet-sized card called a “Survivor Health Passport” can provide patients a portable cheat sheet of their treatment history.
read article 

New Research Study Shows Huge Savings for Health Care

(Wayne State University) June 30, 2014 - Recently published findings in Annals of Internal Medicine by Steven Lipshultz, M.D., Wayne State University professor and chair of pediatrics and pediatrician-in-chief at the Children’s Hospital of Michigan, part of the Detroit Medical Center, and colleagues could help to reduce health care charges while also protecting childhood cancer survivors from heart ailments caused by drug therapy.
read press release 

Drugmakers Taking a Shot at Cancer with Vaccines

(San Francisco Chronicle) July 1, 2014 - In the fight against cancer, biopharmaceutical companies are seeing new promise in weapons that could be more powerful and safer than many existing treatments: vaccines.
read article 

OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment

(OncoGenex) July 1, 2014 - OncoGenex Pharmaceuticals, Inc. today announced initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in previously untreated patients with advanced squamous cell lung cancer.
read corporate press release 

Threshold Pharmaceuticals Initiates 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial of TH-302 in Combination With Pemetrexed in Advanced Non-Squamous Non-Small Cell Lung Cancer

(MarketWatch) July 1, 2014 - Threshold Pharmaceuticals, Inc. today announced initiation of a 440-patient, randomized, double-blind, placebo-controlled trial of its investigational hypoxia-activated prodrug, TH-302, in combination with pemetrexed in advanced non-squamous non-small cell lung cancer (NSCLC).
read article 

CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients with Myelofibrosis

(Yahoo! Finance) July 1, 2014 - CTI BioPharma Corp. announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis.
read article 

Moffitt Cancer Center Researchers Develop New Way to Combat Drug Resistance for Melanoma Patients

(Moffitt) June 30, 2014 - Moffitt Cancer Center researchers developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma.
read press release 

New Approach Identifies Cancer Mutations as Targets of Effective Melanoma Immunotherapy

(AACR) July 1, 2014 - A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy.
read press release 

Surgical Treatment for Metastatic Melanoma of the Liver Increases Overall Survival in a Select Group of Patients

(American College of Surgeons) June 30, 2014 - New Journal of the American College of Surgeons study reports that surgical treatment increases survival for metastatic melanoma patients whose disease is limited to the liver and—when combined with systemic therapy—holds promise for more patients to do well.
read press release